Wow BH This drug looks like to be a better promise than Hydroxyquloroquine to treat the deadly viruse for the fact that it showed grate results on patients who had bin already hospitalized which the Hydroxyquloroquine isnt showing big miricals there So lets hope
אן ארטיקל ערשינען פרייטאג אין דעם לאס אנדזשלעס טיימס,
Malaria drugs fail to help coronavirus patients in controlled studies
More Good News on Remdesivir's Power to Treat COVID-19 from US NEWS TUESDAY, April 21, 2020 (HealthDay News) -- Preliminary data from two clinical trials using the antiviral drug remdesivir to treat COVID-19 patients is encouraging, researchers report. One trial is providing the drug to patients with moderate illness and the other focuses on patients with severe illness. A number of the patients are now recovering and have been released from the hospital. While it's too early to tell, the researchers said there are also indications that remdesivir can possibly stave off being put on a ventilator. "Early results are promising, and that is important right now. Much of what we are learning about COVID-19 management is centered around preventing quick deterioration. Timing is everything. I can't say for certain they [patients] would have been intubated otherwise, but it's encouraging," said Katherine Perez, an infectious diseases pharmacist who is co-leading the trials. Houston Methodist Hospital was the fifth site in the United States to join the clinical trials with remdesivir, and it began enrolling and treating patients in mid-March. Now, these Phase 3 trials will evaluate the effectiveness and safety of remdesivir. Both trials are registered with the federal government's clinical trial registry. The patients with moderate illness receive either five or 10 days of remdesivir treatment, while those with severe illness receive 10 days of treatment with the drug. Quick treatment is critical, said Dr. Kevin Grimes, an infectious diseases physician and co-leader of the trials. "If given early enough, we're hoping that remdesivir interferes with the virus and blocks its ability to replicate in patients' cells," Grimes said in a Houston Methodist news release. "The goal is that it staves off the deadly inflammatory cascade that leads to respiratory failure and the need to be intubated and put on a ventilator. Remdesivir was originally developed to treat Ebola more than a decade ago. It's known to be generally safe in humans, the researchers said, and is backed by a large body of preclinical research, and a number of studies have shown it stops SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome), the viral cousins of COVID-19. And other studies have suggested that it's effective against the new coronavirus. A study in China earlier this year showed that remdesivir could block COVID-19 from replicating in human cells, and a case report in the New England Journal of Medicine (NEJM) focused on the man in Washington state who was the first known U.S. COVID-19 patient. He received remdesivir, made by Gilead Sciences, and he started improving within 24 hours. The first results from one of Gilead's compassionate-use trials was published earlier this month in the NEJM. The study showed clinical improvement in two-thirds of patients hospitalized for severe COVID-19 who received the antiviral. Meanwhile, forthcoming reports from several ongoing clinical trials -- including the ones at Houston Methodist -- will provide more evidence-based data about the use of remdesivir for treating COVID-19 patients.
The results of a highly anticipated study on an experimental coronavirus treatment for the sickest patients are expected any day.
Physicians leading the clinical trial for the drug, called remdesivir, say the fast-moving pandemic has compelled them to work with haste, all without compromising the scientific rigor necessary to prove whether the drug really works. "We are in a race against time," Dr. Andre Kalil, a principal investigator for the trial at the University of Nebraska Medical Center, told NBC News. "We're doing everything we can 24/7 to make this happen."
Previous research hinted at the promise of remdesivir, an antiviral drug that's thought to work by blocking the virus from replicating itself in the body. But those studies were either based on animal data or had major caveats, such as lacking a control group.
A study published earlier this month in the New England Journal of Medicine found the drug improved breathing in some patients, but the study was small, with just 53 patients. And its authors did not compare their patients' outcomes with a control group of patients to know for sure whether the improvements were truly due to remdesivir, or whether they would have become better on their own, without treatment.
The ongoing clinical trial at the University of Nebraska Medical Center, in partnership with dozens of other sites globally, does have a control group.
The trial is sponsored by the National Institutes of Health. Gilead Sciences, which developed the drug, is also involved.
"This is something that we have to do as perfectly as possible," Kalil said. "You have to have reliable data. It's the soul of the whole study."
Researchers must also carefully scrutinize any side effects that may be associated with the drug. Mild to moderate liver function abnormalities have been noted previously. If remdesivir proves to be safe and effective against the coronavirus, Kalil said the trial will pivot to studying other drugs. The investigators would use remdesivir as the control, and see how well other drugs compare.
One treatment on deck is called baricitinib, an anti-inflammatory medication used to treat rheumatoid arthritis.
"There is hope that this medication can bring down inflammation and help prevent the spread of the virus from one cell to another," Kalil said.
A potential antiviral drug for the coronavirus has reportedly failed in its first randomised clinical trial.
There had been widespread hope that remdesivir could treat Covid-19.
But a Chinese trial showed that the drug had not been successful, according to draft documents accidentally published by the World Health Organization.
The drug did not improve patients' condition or reduce the pathogen's presence in the bloodstream, it said.
The US firm behind the drug, Gilead Sciences, said the document had mischaracterised the study.
What do we know about the study? News of the failed trial spread after the WHO posted details on its clinical trials database, before it was removed. The WHO has since confirmed the draft report was mistakenly uploaded.
It showed that researchers studied 237 patients, administering the drug to 158 and comparing their progress with the remaining 79, who received a placebo.
After a month, 13.9% of the patients taking the drug had died compared to 12.8% of those receiving the placebo. The trial was stopped early because of side-effects.
"Remdesivir was not associated with clinical or virological benefits," the summary states.
All three main US stock indexes fell back from gains of over 1% after the news broke over the trial.
די סטאדי האט אנגעפאנגן געבן די דראג 12 טעג נאך סימפטאטען זענען ארויס געקומען
כאשט וואס סייד עפעקטס ביי ביידע גרופעס זענען געווען די זעלבע, האבן מער מענטשען וואס האבן גענומען די דראג מחליט געווען צו אויפהערען נאמען די דראג ווי מענטשען וואס האבן אויפגעהערט נעמען די placebo
די סטאדי האט זיך געענדיגט פרי, ווייל זיי האבן נישט געהאט גענוג מענטשען אויף וועם צו טעסטען
חוץ מזה וואס דאס איז נישט קיין אפישעל סטאדי רוזאלטס, ס'איז נאר א ליעק, און די סטאדי איז דערווייל נישט peer-reviewed.
נישט אזוי טיף צו פארשטיין פשוט היידראקסיקלאראקווין איז טראמפ געווען ביזי מיט האבן זיי געמוזט נאר טרעפן אז עס ארבייט נישט אין אז מען טרעפט עפעס אנדערש אין מען קען זאגן יענץ ארבייט אין היידראקסיקלאראקווין נישט איז דאס נאך בעסער
דבר פשוט מאוד, אנטי טראמפיסטן וואס האבן געוואלט זעהן א רפואה, אבער געוואלט טראמפ זאל פלאפן, האבן געלעכצט אז רעמדיסיווער זאל זיך אויסארבעטן. טראמפיסטן פון די אנדערע זייט האבן געוואלט אז קלאראקווין זאל זיך אויסארבעטן.
למעשה עדיין לא נושענו נאר ביידע קוקט אויס זענען גארנישט ווערט.
Army war on COVID-19 saves soldiers’ lives with remdesivir anti-viral drug It is a mysterious, unseen, not-fully understood, yet highly contagious threat -- that is killing Americans. There is no human enemy … no state, group, or known attacker, yet 1 million people in the U.S. have been infected, with millions more at risk.
COVID-19 is more than a national distraction, but a very serious and lethal problem. So… in support of the Pentagon, White House and whole-of-government effort … the U.S. Army has waged war on coronavirus. No guns are being fired, no tanks are advancing, no drones are launching missiles and no humans are being attacked. But the Army is immersed in an all-out offensive on the “virus.”
What does this look like? There are a wide range of nuances to the Army assault on COVID, including research and testing of vaccines, personnel support to the White House Task Force, delivery of PPE, antibody research, the pursuit of testing applications and technologies and … perhaps of greatest importance ... medical efforts to save, heal and safeguard those injured and at risk. Doctors explain that successful COVID recovery often emerges following a frightening, delicate and precarious dangling upon a thin boundary between life and death. Many are being saved. With this priority in the forefront, the Army war on COVID is showing promise and progress on several fronts.
One area of initial success includes Army-driven treatment innovations, including the “investigational” use of a drug called remdesivir.
“So far we have seen success with remdesivir to the point where we have gotten a few service members excavated and actually discharged. We started a month ago at Landstuhl (Army Medical Center in Germany) and a few medical centers throughout DoD. I think we are up to 10 medical centers now,” Gen. John Murray, Commander, Army Futures Command, told Warrior in an interview.
While hopeful, Murray was careful to explain that progress is preliminary and has not involved a “huge sampling or huge testing population. It is very early on, but it is showing some promise,” Murray said.
Use of the drug emerges from a cooperative research agreement between an element of Army Futures Command called the U.S. Army Medical Materiel Development Activities Force Health Protection program and scientists from biopharmaceutical company Gilead, Army officials explained.
As Murray indicated, Army officials involved in the effort told Warrior “this is not a clinical trial but a treatment protocol which the Force Health Protection Division allows for the investigational use of remdesivir to treat DOD personnel diagnosed with moderate-severe COVID-19.”
Interestingly, the drug saves monkeys. The Army’s initial findings regarding remdesivir completely align with an April 17 paper from the National Institute of Health called “Antiviral Remdesivir Prevents Disease Progression in Monkeys with COVID 19.”
Amazingly, the scientists found “six treated animals in significantly better health than the untreated group … the amount of virus found in the lungs was significantly lower in the treatment group compared to the untreated group, and SARS-CoV-2 caused less damage to the lungs in treated animals than in untreated animals,” the paper explains.
Again, as explained by Murray, the NIH paper also advises that the findings “should not be considered clinical advice, but are being shared to assist the public health response to COVID 19.”
Naturally, further testing, exploration and “investigation” of remdesivir is ongoing for several reasons. First, there are no vaccines or specific known treatments for the mysterious COVID and … of greatest importance … lives are at stake “right now.” People are dying.
FDA reportedly will approve Covid-19 treatment remdesivir, which US-funded trial shows has 'positive effect' on recovery Researchers released some good news about a possible treatment for coronavirus Wednesday -- evidence that the experimental drug remdesivir might help patients recover more quickly from the infection.
The US Food and Drug Administration has not yet approved any drugs for the treatment of the coronavirus. But it plans to announce an emergency-use authorization for remdesivir, according to The New York Times. The authorization could come as soon as Wednesday, The Times reported, citing a senior administration official. In a statement to CNN, the FDA said it is in talks with Gilead Sciences, the maker of remdesivir, about making the drug available to patients. "As part of the FDA's commitment to expediting the development and availability of potential COVID-19 treatments, the agency has been engaged in ... discussions with Gilead Sciences regarding making remdesivir available to patients as quickly as possible, as appropriate," FDA spokesman Michael Felberbaum said in statement. The government-funded study found that patients who took remdesivir recovered faster than patients who did not. It's not a home run, but federal officials are keen to provide any hope they can in a pandemic that has infected more than 1 million Americans and killed close to 60,000 of them. The head of the National Institute of Allergy and Infectious Diseases was optimistic about the results. "The data shows that remdesivir has a clear-cut, significant, positive effect in diminishing the time to recovery," Fauci said at the White House during a meeting with President Donald Trump. Results from the preliminary trial show remdesivir improved recovery time for coronavirus patients from 15 to 11 days. That's similar to the effect that the influenza drug Tamiflu has on flu. Tamiflu also doesn't cure patients quickly, but can reduce how long they are sick. "Although a 31% improvement doesn't seem like a knockout 100%, it is very important proof of concept," Fauci said of remdesivir. "What it has proven is that a drug can block this virus." Remdesivir also may reduce the likelihood that patients will die. "Results also suggested a survival benefit, with a mortality rate of 8.0% for the group receiving remdesivir versus 11.6% for the placebo group," the NIAID said. Normally, data about a drug's efficacy wouldn't be released this early from a preliminary trial. But "whenever you have clear-cut evidence that a drug works, you have an ethical obligation to immediately let the people in the placebo group know so that they can have access," Fauci said. Remdesivir is among several drugs being tested against Covid-19, but the NIAID trial is the first conducted according to rules aimed at gaining FDA approval. About 1,090 people participated in the trial internationally, Fauci said, calling it "the first truly high-powered randomized placebo controlled trial."
But the World Health Organization said it's too early to comment on the remdesivir trial results released Wednesday. "Typically, you don't have one study that will come out that will be a game changer," said Dr. Maria Van Kerkhove, the WHO's technical lead for the coronavirus response. She said the agency generally pulls together evidence from several studies before reviewing and critiquing the evidence. "It can sometimes take a number of publications to determine (what) the ultimate impact of a drug is," said Dr. Mike Ryan, executive director of the WHO's health emergencies program.
